Review



apparent diffusion coefficient adc images  (Bruker Corporation)


Bioz Verified Symbol Bruker Corporation is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Bruker Corporation apparent diffusion coefficient adc images
    Apparent Diffusion Coefficient Adc Images, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 2972 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pm39623451-125-0-14?v=Bruker+Corporation
    Average 97 stars, based on 2972 article reviews
    apparent diffusion coefficient adc images - by Bioz Stars, 2026-08
    97/100 stars

    Images



    Similar Products

    apparent diffusion coefficient adc maps  (Philips Healthcare)
    86
    Philips Healthcare apparent diffusion coefficient adc maps
    Apparent Diffusion Coefficient Adc Maps, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pmc12970932-151-20-5?v=Philips+Healthcare
    Average 86 stars, based on 1 article reviews
    apparent diffusion coefficient adc maps - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient adc  (Takeda)
    86
    Takeda apparent diffusion coefficient adc
    Apparent Diffusion Coefficient Adc, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pmc12968903-115-28-2?v=Takeda
    Average 86 stars, based on 1 article reviews
    apparent diffusion coefficient adc - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health apparent diffusion coefficient
    Apparent Diffusion Coefficient, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/10__1097_slash_rct__0000000000001827-119-2-25?v=Wolters+Kluwer+Health
    Average 86 stars, based on 1 article reviews
    apparent diffusion coefficient - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient adc maps  (Bruker Corporation)
    97
    Bruker Corporation apparent diffusion coefficient adc maps
    A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
    Apparent Diffusion Coefficient Adc Maps, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/bio_rxiv__2025__10__22__684053-75-0-10?v=Bruker+Corporation
    Average 97 stars, based on 1 article reviews
    apparent diffusion coefficient adc maps - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient adc images  (Bruker Corporation)
    97
    Bruker Corporation apparent diffusion coefficient adc images
    A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
    Apparent Diffusion Coefficient Adc Images, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pm39623451-125-0-14?v=Bruker+Corporation
    Average 97 stars, based on 1 article reviews
    apparent diffusion coefficient adc images - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient (adc)  (Siemens Healthineers)
    90
    Siemens Healthineers apparent diffusion coefficient (adc)
    A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
    Apparent Diffusion Coefficient (Adc), supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pm39026152-51-22-27?v=Siemens+Healthineers
    Average 90 stars, based on 1 article reviews
    apparent diffusion coefficient (adc) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient adc  (Siemens Healthineers)
    86
    Siemens Healthineers apparent diffusion coefficient adc
    A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
    Apparent Diffusion Coefficient Adc, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pmc11264621-80-22-27?v=Siemens+Healthineers
    Average 86 stars, based on 1 article reviews
    apparent diffusion coefficient adc - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    apparent diffusion coefficient  (Bruker Corporation)
    97
    Bruker Corporation apparent diffusion coefficient
    Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion <t>coefficient.</t> (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.
    Apparent Diffusion Coefficient, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apparent+diffusion+coefficient/pm38862251-197-1-14?v=Bruker+Corporation
    Average 97 stars, based on 1 article reviews
    apparent diffusion coefficient - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion coefficient (ADC) observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.

    Journal: bioRxiv

    Article Title: Multimodal Characterization and Evolution of Malonate-induced Stroke Model: Advanced MRI, Histology-Molecular Profiling

    doi: 10.1101/2025.10.22.684053

    Figure Lengend Snippet: A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion coefficient (ADC) observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.

    Article Snippet: Apparent diffusion coefficient (ADC) maps were automatically computed on the Bruker scanner as the means of the ADCs observed in each of three orthogonal directions.

    Techniques: Diffusion-based Assay, Injection, MANN-WHITNEY

    Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.

    Journal: Journal for immunotherapy of cancer

    Article Title: Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.

    doi: 10.1136/jitc-2023-008475

    Figure Lengend Snippet: Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.

    Article Snippet: ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360.

    Techniques: Diffusion-based Assay, Gene Expression, Immunofluorescence, Comparison, Staining